Adagio Therapeutics Announces CEO Succession Plan

WALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the...

Related Keywords

United States ,America ,Tillman Gerngross ,David Hering ,Harvard Business School ,Pfizer ,Adagio Therapeutics Inc ,Sard Verbinnen Co ,Cornell University ,Nasdaq ,Chief Executive Officer ,Chief Operating Officer ,Interim Chief Executive Officer ,Private Securities Litigation Reform Act ,Quarterly Report ,Nasdaq Adgi ,Adagio Therapeutics ,Nc ,